Standard BioTools Aktie

Standard BioTools Forward P/E

Forward P/E-forhold for Standard BioTools (LAB) pr. 18. aug. 2026 er -5,75. I foregående år var Forward P/E-forhold -3,10 — en ændring på 85,44 % (lavere).

Forward P/E

-5,75

YoY

85,44%

Senest opdateret:

Forward P/E-forhold for Standard BioTools er 2026 -5,75 . Forward P/E-forhold for Standard BioTools var 2025 -3,10 . Det falder dermed med 85,44% lavere sammenlignet med året før.
Access this data via the Eulerpool API

Standard BioTools Aktieanalyse

Hvad laver Standard BioTools? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Standard BioTools aktie

Forward P/E-forhold for Standard BioTools er -5,75 i 2026.

Forward P/E-forhold for Standard BioTools ændrede sig fra -3,10 til -5,75, hvilket repræsenterer en ændring på 85,44 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Forward P/E-forhold Standard BioTools siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Forward P/E bruger estimeret fremtidig indtjening til at værdiansætte en aktie. Et lavere forward P/E i forhold til bagudrettet P/E tyder på, at analytikere forventer vækst i indtjeningen.

For at evaluere Forward P/E-forholds er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for Forward P/E-forhold.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne Forward P/E-forholds Standard BioTools med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

Access this data via the Eulerpool API

Værdiansættelse — Standard BioTools

Alle nøgletal — Standard BioTools